194 related articles for article (PubMed ID: 22323743)
21. Olfaction and imaging biomarkers in premotor LRRK2 G2019S-associated Parkinson disease.
Sierra M; Sánchez-Juan P; Martínez-Rodríguez MI; González-Aramburu I; García-Gorostiaga I; Quirce MR; Palacio E; Carril JM; Berciano J; Combarros O; Infante J
Neurology; 2013 Feb; 80(7):621-6. PubMed ID: 23325906
[TBL] [Abstract][Full Text] [Related]
22. The LRRK2 G2019S mutation as the cause of Parkinson's disease in Ashkenazi Jews.
Thaler A; Ash E; Gan-Or Z; Orr-Urtreger A; Giladi N
J Neural Transm (Vienna); 2009 Nov; 116(11):1473-82. PubMed ID: 19756366
[TBL] [Abstract][Full Text] [Related]
23. The LRRK2 G2019S mutation status does not affect the outcome of subthalamic stimulation in patients with Parkinson's disease.
Greenbaum L; Israeli-Korn SD; Cohen OS; Elincx-Benizri S; Yahalom G; Kozlova E; Strauss H; Molshatzki N; Inzelberg R; Spiegelmann R; Israel Z; Hassin-Baer S
Parkinsonism Relat Disord; 2013 Nov; 19(11):1053-6. PubMed ID: 23932063
[TBL] [Abstract][Full Text] [Related]
24. The LRRK2 G2019S mutation in a series of Argentinean patients with Parkinson's disease: clinical and demographic characteristics.
Gatto EM; Parisi V; Converso DP; Poderoso JJ; Carreras MC; Martí-Massó JF; Paisán-Ruiz C
Neurosci Lett; 2013 Mar; 537():1-5. PubMed ID: 23340200
[TBL] [Abstract][Full Text] [Related]
25. Low-variance RNAs identify Parkinson's disease molecular signature in blood.
Chikina MD; Gerald CP; Li X; Ge Y; Pincas H; Nair VD; Wong AK; Krishnan A; Troyanskaya OG; Raymond D; Saunders-Pullman R; Bressman SB; Yue Z; Sealfon SC
Mov Disord; 2015 May; 30(6):813-21. PubMed ID: 25786808
[TBL] [Abstract][Full Text] [Related]
26. Age at Onset of Parkinson's Disease Among Ashkenazi Jewish Patients: Contribution of Environmental Factors, LRRK2 p.G2019S and GBA p.N370S Mutations.
Yahalom G; Rigbi A; Israeli-Korn S; Krohn L; Rudakou U; Ruskey JA; Benshimol L; Tsafnat T; Gan-Or Z; Hassin-Baer S; Greenbaum L
J Parkinsons Dis; 2020; 10(3):1123-1132. PubMed ID: 32310186
[TBL] [Abstract][Full Text] [Related]
27. Clinical features of LRRK2-associated Parkinson's disease in central Norway.
Aasly JO; Toft M; Fernandez-Mata I; Kachergus J; Hulihan M; White LR; Farrer M
Ann Neurol; 2005 May; 57(5):762-5. PubMed ID: 15852371
[TBL] [Abstract][Full Text] [Related]
28. Glucocerebrosidase activity in Parkinson's disease with and without GBA mutations.
Alcalay RN; Levy OA; Waters CC; Fahn S; Ford B; Kuo SH; Mazzoni P; Pauciulo MW; Nichols WC; Gan-Or Z; Rouleau GA; Chung WK; Wolf P; Oliva P; Keutzer J; Marder K; Zhang X
Brain; 2015 Sep; 138(Pt 9):2648-58. PubMed ID: 26117366
[TBL] [Abstract][Full Text] [Related]
29. High frequency and reduced penetrance of LRRK2 G2019S mutation among Parkinson's disease patients in Cantabria (Spain).
Sierra M; González-Aramburu I; Sánchez-Juan P; Sánchez-Quintana C; Polo JM; Berciano J; Combarros O; Infante J
Mov Disord; 2011 Nov; 26(13):2343-6. PubMed ID: 21954089
[TBL] [Abstract][Full Text] [Related]
30. A study of LRRK2 mutations and Parkinson's disease in Brazil.
Pimentel MM; Moura KC; Abdalla CB; Pereira JS; de Rosso AL; Nicaretta DH; Campos M; de Almeida RM; dos Santos JM; Bastos IC; Mendes MF; Maultasch H; Costa FH; Werneck AL; Santos-Rebouças CB
Neurosci Lett; 2008 Mar; 433(1):17-21. PubMed ID: 18201824
[TBL] [Abstract][Full Text] [Related]
31. Nonmotor symptoms in healthy Ashkenazi Jewish carriers of the G2019S mutation in the LRRK2 gene.
Mirelman A; Alcalay RN; Saunders-Pullman R; Yasinovsky K; Thaler A; Gurevich T; Mejia-Santana H; Raymond D; Gana-Weisz M; Bar-Shira A; Ozelius L; Clark L; Orr-Urtreger A; Bressman S; Marder K; Giladi N;
Mov Disord; 2015 Jun; 30(7):981-6. PubMed ID: 25809001
[TBL] [Abstract][Full Text] [Related]
32. Fall risk and gait in Parkinson's disease: the role of the LRRK2 G2019S mutation.
Mirelman A; Heman T; Yasinovsky K; Thaler A; Gurevich T; Marder K; Bressman S; Bar-Shira A; Orr-Urtreger A; Giladi N; Hausdorff JM;
Mov Disord; 2013 Oct; 28(12):1683-90. PubMed ID: 24123150
[TBL] [Abstract][Full Text] [Related]
33. Glucocerebrosidase mutations are not found in association with LRRK2 G2019S in subjects with parkinsonism.
Eblan MJ; Scholz S; Stubblefield B; Gutti U; Goker-Alpan O; Hruska KS; Singleton AB; Sidransky E
Neurosci Lett; 2006 Aug; 404(1-2):163-5. PubMed ID: 16781064
[TBL] [Abstract][Full Text] [Related]
34. Olfactory dysfunction in LRRK2 G2019S mutation carriers.
Saunders-Pullman R; Stanley K; Wang C; San Luciano M; Shanker V; Hunt A; Severt L; Raymond D; Ozelius LJ; Lipton RB; Bressman SB
Neurology; 2011 Jul; 77(4):319-24. PubMed ID: 21753159
[TBL] [Abstract][Full Text] [Related]
35. Clustering of motor and nonmotor traits in leucine-rich repeat kinase 2 G2019S Parkinson's disease nonparkinsonian relatives: A multicenter family study.
Mestre TA; Pont-Sunyer C; Kausar F; Visanji NP; Ghate T; Connolly BS; Gasca-Salas C; Kern DS; Jain J; Slow EJ; Faust-Socher A; Kasten M; Wadia PM; Zadikoff C; Kumar P; de Bie RM; Thomsen T; Lang AE; Schüle B; Klein C; Tolosa E; Marras C
Mov Disord; 2018 Jul; 33(6):960-965. PubMed ID: 29665080
[TBL] [Abstract][Full Text] [Related]
36. Genetic screening for the LRRK2 R1441C and G2019S mutations in Parkinsonian patients from Campania.
De Rosa A; De Michele G; Guacci A; Carbone R; Lieto M; Peluso S; Picillo M; Barone P; Salemi F; Laiso A; Saccà F; Tessitore A; Pellecchia MT; Bonifati V; Criscuolo C
J Parkinsons Dis; 2014; 4(1):123-8. PubMed ID: 24496098
[TBL] [Abstract][Full Text] [Related]
37. [Clinical features of LRRK2-associated Parkinson's disease].
Pchelina SN; Ivanova ON; Emel'ianov AK; Iakimovskiĭ AF
Zh Nevrol Psikhiatr Im S S Korsakova; 2011; 111(12):56-62. PubMed ID: 22433811
[TBL] [Abstract][Full Text] [Related]
38. Prevalence and clinical features of common LRRK2 mutations in Australians with Parkinson's disease.
Huang Y; Halliday GM; Vandebona H; Mellick GD; Mastaglia F; Stevens J; Kwok J; Garlepp M; Silburn PA; Horne MK; Kotschet K; Venn A; Rowe DB; Rubio JP; Sue CM
Mov Disord; 2007 May; 22(7):982-9. PubMed ID: 17427941
[TBL] [Abstract][Full Text] [Related]
39. LRRK2 gene in Parkinson disease: mutation analysis and case control association study.
Paisán-Ruíz C; Lang AE; Kawarai T; Sato C; Salehi-Rad S; Fisman GK; Al-Khairallah T; St George-Hyslop P; Singleton A; Rogaeva E
Neurology; 2005 Sep; 65(5):696-700. PubMed ID: 16157901
[TBL] [Abstract][Full Text] [Related]
40. Cognitive and behavioral symptoms in Parkinson's disease patients with the G2019S and R1441G mutations of the LRRK2 gene.
Somme JH; Molano Salazar A; Gonzalez A; Tijero B; Berganzo K; Lezcano E; Fernandez Martinez M; Zarranz JJ; Gómez-Esteban JC
Parkinsonism Relat Disord; 2015 May; 21(5):494-9. PubMed ID: 25840672
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
